JP2007520537A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007520537A5 JP2007520537A5 JP2006551904A JP2006551904A JP2007520537A5 JP 2007520537 A5 JP2007520537 A5 JP 2007520537A5 JP 2006551904 A JP2006551904 A JP 2006551904A JP 2006551904 A JP2006551904 A JP 2006551904A JP 2007520537 A5 JP2007520537 A5 JP 2007520537A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- chlorophenylamino
- amide
- carboxylic acid
- acceptable derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 3
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 208000026278 immune system disease Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- HZXOTOOHIVUIJU-UHFFFAOYSA-N 2-(3-chloroanilino)-4-[1-(dimethylamino)ethyl]-n-(oxan-4-ylmethyl)pyrimidine-5-carboxamide;hydrochloride Chemical compound Cl.N=1C=C(C(=O)NCC2CCOCC2)C(C(N(C)C)C)=NC=1NC1=CC=CC(Cl)=C1 HZXOTOOHIVUIJU-UHFFFAOYSA-N 0.000 claims 1
- WVYZUZIUQXMOHF-UHFFFAOYSA-N 2-(3-chloroanilino)-4-ethyl-n-(oxan-4-ylmethyl)pyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)NCC2CCOCC2)C(CC)=NC=1NC1=CC=CC(Cl)=C1 WVYZUZIUQXMOHF-UHFFFAOYSA-N 0.000 claims 1
- ZJERRCJPKOZJGT-UHFFFAOYSA-N 2-(3-chloroanilino)-n-(oxan-4-ylmethyl)-4-propan-2-ylpyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)NCC2CCOCC2)C(C(C)C)=NC=1NC1=CC=CC(Cl)=C1 ZJERRCJPKOZJGT-UHFFFAOYSA-N 0.000 claims 1
- ZKWKIJXNDPVRFZ-UHFFFAOYSA-N 2-(3-chloroanilino)-n-cyclohexyl-4-ethyl-n-methylpyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)N(C)C2CCCCC2)C(CC)=NC=1NC1=CC=CC(Cl)=C1 ZKWKIJXNDPVRFZ-UHFFFAOYSA-N 0.000 claims 1
- PZRWJUYHONADFH-UHFFFAOYSA-N 2-(3-chloroanilino)-n-cyclohexyl-n-methyl-4-propan-2-ylpyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)N(C)C2CCCCC2)C(C(C)C)=NC=1NC1=CC=CC(Cl)=C1 PZRWJUYHONADFH-UHFFFAOYSA-N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 3
- 208000020401 Depressive disease Diseases 0.000 description 3
- 206010041250 Social phobia Diseases 0.000 description 3
- 208000026139 Memory disease Diseases 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 2
- 229940025084 amphetamine Drugs 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 208000024714 major depressive disease Diseases 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 208000008811 Agoraphobia Diseases 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 208000022214 Post-traumatic amnestic disease Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 208000027520 Somatoform disease Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 208000025307 bipolar depression Diseases 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 206010007776 catatonia Diseases 0.000 description 1
- 230000002060 circadian Effects 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 201000003104 endogenous depression Diseases 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- 229960001252 methamphetamine Drugs 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 208000025319 neurotic depression Diseases 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 208000027753 pain disease Diseases 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 229950010883 phencyclidine Drugs 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000000698 schizophrenic effect Effects 0.000 description 1
- 208000012672 seasonal affective disease Diseases 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 208000018726 traumatic encephalopathy Diseases 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0402356.0A GB0402356D0 (en) | 2004-02-03 | 2004-02-03 | Novel compounds |
| PCT/GB2005/000341 WO2005075440A1 (en) | 2004-02-03 | 2005-02-01 | 2- (phenylamino) -pyrimidin-5-amides as cannabinoid 2 receptors modulators for the treatment of immune or inflammatory disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007520537A JP2007520537A (ja) | 2007-07-26 |
| JP2007520537A5 true JP2007520537A5 (enExample) | 2008-03-21 |
Family
ID=31985568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006551904A Withdrawn JP2007520537A (ja) | 2004-02-03 | 2005-02-01 | 免疫病または炎症障害を治療するためのカンナビノイド２受容体の調節剤としての２−（フェニルアミノ）−ピリミジン−５−アミド |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20090264452A1 (enExample) |
| EP (1) | EP1711475A1 (enExample) |
| JP (1) | JP2007520537A (enExample) |
| GB (1) | GB0402356D0 (enExample) |
| WO (1) | WO2005075440A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7763607B2 (en) | 2006-04-27 | 2010-07-27 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators |
| MX2008013285A (es) * | 2006-04-27 | 2008-10-24 | Solvay Pharm Gmbh | Uso novedoso de moduladores del receptor canabinoide cbx como moduladores de los canales de potasio. |
| US7781593B2 (en) | 2006-09-14 | 2010-08-24 | Hoffmann-La Roche Inc. | 5-phenyl-nicotinamide derivatives |
| RU2011143740A (ru) | 2009-03-30 | 2013-05-10 | Астеллас Фарма Инк. | Соединение пиримидина |
| CN113109571B (zh) * | 2021-03-19 | 2023-05-05 | 浙江工商大学 | 一种用于评估个体过敏程度的试剂盒 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5112820A (en) * | 1990-03-05 | 1992-05-12 | Sterling Drug Inc. | Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof |
| HUT63941A (en) * | 1992-05-15 | 1993-11-29 | Hoechst Ag | Process for producing 4-alkyl-substituted pyrimidine-5-carboxanilide derivatives, and fungicidal compositions comprising same |
| WO1997009315A1 (en) * | 1995-09-01 | 1997-03-13 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions |
| FR2742148B1 (fr) * | 1995-12-08 | 1999-10-22 | Sanofi Sa | Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant |
| GB0016877D0 (en) * | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
| HUP0303841A2 (hu) * | 2001-02-20 | 2004-03-01 | Bristol-Myers Squibb Company | 2,4-Diszubsztituált-5-pirimidinkarboxamid-származékok mint KCNQ káliumcsatorna modulátorok és ezeket tartalmazó gyógyszerkészítmények és előállításuk |
| UY27939A1 (es) * | 2002-08-21 | 2004-03-31 | Glaxo Group Ltd | Compuestos |
| ES2273077T3 (es) * | 2002-08-21 | 2007-05-01 | Glaxo Group Limited | Derivados de 2-fenilamino-4-trifluorometil-5 (bencil- o piridin-4-il-metil) carbamoilpirimidina como moduladores selectivos del receptor cannabinoide cb2. |
| GB0222495D0 (en) * | 2002-09-27 | 2002-11-06 | Glaxo Group Ltd | Compounds |
| GB0222493D0 (en) * | 2002-09-27 | 2002-11-06 | Glaxo Group Ltd | Compounds |
-
2004
- 2004-02-03 GB GBGB0402356.0A patent/GB0402356D0/en not_active Ceased
-
2005
- 2005-02-01 EP EP05702083A patent/EP1711475A1/en not_active Withdrawn
- 2005-02-01 JP JP2006551904A patent/JP2007520537A/ja not_active Withdrawn
- 2005-02-01 US US10/597,476 patent/US20090264452A1/en not_active Abandoned
- 2005-02-01 WO PCT/GB2005/000341 patent/WO2005075440A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2293731C2 (ru) | Производные пиридина и пиримидина, способы их получения (варианты), фармацевтическая композиция и применение | |
| JP6542212B2 (ja) | ブロモドメイン阻害剤としての新規キナゾリノン | |
| CN101679287B (zh) | 烟碱型乙酰胆碱受体调节剂 | |
| KR101562835B1 (ko) | 치료제 | |
| CN1419552A (zh) | 2－氨基－3－烷基嘧啶酮衍生物作为GSK3β抑制剂 | |
| JP2022513959A (ja) | 大環状化合物及び疾患の処置におけるそれらの使用 | |
| TWI224102B (en) | Serotonergic agents | |
| JP2007520539A5 (enExample) | ||
| AU2016370554A1 (en) | Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels | |
| CN105121439A (zh) | 作为pde4亚型抑制剂用于治疗cns和其他病症的氮杂苯并咪唑化合物 | |
| JP2013537887A5 (enExample) | ||
| JP2005526723A5 (enExample) | ||
| JP2010506851A (ja) | 二環式ヘテロ芳香族化合物 | |
| MXPA04007502A (es) | Derivados de quinolina como antagonistas de neuropeptido y (npy). | |
| JP2008500336A (ja) | 治療化合物：骨格としてのピリジン | |
| JP2008501758A5 (enExample) | ||
| ES2222396T3 (es) | Compuestos utiles como ingrediente activo de un medicamento para el tratamiento preventivo y/o terapeutico de enfermedades neurodegenerativas. | |
| CN107108478A (zh) | Urat1抑制剂 | |
| JP5822079B2 (ja) | 疼痛治療剤 | |
| JP2008543782A (ja) | ５−ｈｔ１ａ受容体のピペラジン−ピペリジンアンタゴニストおよびアゴニスト | |
| JP2014518281A (ja) | 電位依存性ナトリウムチャネル遮断薬 | |
| JP2009542661A5 (enExample) | ||
| JP4885709B2 (ja) | ピリジニルアセトニトリル類 | |
| JP2007523206A5 (enExample) | ||
| JP2007520537A5 (enExample) |